In NSG mice bearing patient-derived AML xenografts, cytarabine at 60 mg/kg/day intraperitoneally for five days reduced marrow and spleen leukemia burden at day 8. Responses varied across models (4–46-fold reduction), residual disease persisted, and some individual comparisons were nonsignificant. [4]
A separate acute high-dose study found increased γ-H2AX in Purkinje-cell nuclei after cytarabine administration to wild-type mice. This damage-response finding limits assumptions of tumor-specific action; its dose, timing and model differ from the AML xenograft study. [5]
Variable cytoreduction in human AML xenografts
Animal study · NSG mice bearing patient-derived AML xenografts; 25 patient specimens in response cohort; groups described as 4–10 mice [4]
AraC reduced aggregate viable AML burden in marrow and spleen at day 8, with 4–46-fold reductions across patient-derived models. Residual leukemia remained; some individual comparisons were nonsignificant.
Conditions shared by the study groups
- Route
- Intraperitoneal injection
- Frequency
- Daily
- Treatment course
- 5 consecutive days; endpoint day 8
- Cytarabine
- Model: NSG AML patient-derived xenograft mice
- Reported limits: AraC formulation and injection volume not specified in adopted passage; day-8 endpoint retained without a post-final-dose interval.
Methods and source locations
Compound reported in the paper: Cytarabine; Compound label in the paper: AraC
Compound-level research evidence; no Adooq lot equivalence. Reported material used as named; no salt conversion.
First Results subsection; Figure 1A,C–D and caption; Methods: Cytarabine treatment and Assessment of leukemic engraftment
Viable human AML burden in bone marrow plus spleen versus vehicle: Flow cytometry; graphs mean ± s.e.m.; some Figure 1C individual tests marked n.s. or n.d. — Figure 1C–D; first Results subsection
Cytarabine · First Results subsection; Figure 1A,C–D and caption; Methods: Cytarabine treatment and Assessment of leukemic engraftment
Acute Purkinje-cell DNA damage response after cytarabine
Animal study · Wild-type C57BL/6J mice, approximately one month old under the default Methods regimen [5]
After high-dose acute AraC exposure, Purkinje-cell nuclear γ-H2AX profiles increased relative to PBS controls. This is a DNA damage response marker, not a behavioral ataxia endpoint or an estimate of toxicity at the AML xenograft regimen.
Conditions shared by the study groups
- Route
- Intraperitoneal injection
- Frequency
- One cycle (single acute administration)
- Treatment course
- 3 h endpoint
- Vehicle
- PBS adjusted to pH 7.0
- Acute cytarabine
- Model: Wild-type C57BL/6J mice
- Reported limits: No behavioral or long-term outcome adopted; no cross-regimen dose conversion.
Methods and source locations
Compound reported in the paper: Cytarabine; Compound label in the paper: AraC
Compound-level adverse-response context; no Adooq lot validation and no clinical dose equivalence.
Figure 4A–C; Results: Ataxia-like transcriptional profile (opening paragraph); Methods: Mice; Nuclei preparation and fluorescence-activated cell sorting
Purkinje-cell nuclear γ-H2AX: Nuclear immunostaining for NeuN, ITPR1 and γ-H2AX; main Figure 4B identifies the Purkinje gate, Figure 4C compares treatment profiles — Figure 4A–C; Results: Ataxia-like transcriptional profile (opening paragraph); Methods: Mice; Nuclei preparation and fluorescence-activated cell sorting
Acute cytarabine · Figure 4A–C; Results: Ataxia-like transcriptional profile (opening paragraph); Methods: Mice; Nuclei preparation and fluorescence-activated cell sorting